Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Neoplasms 4Triple Negative Breast Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Neoplasm Metastasis 2Endometrial Neoplasms 2Breast Neoplasms 2Bile Duct Neoplasms 2Uterine Cervical Neoplasms 1Solid Tumour Refractory to Conventional Treatment 1Small Cell Lung Carcinoma 1SCLC 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Non Small Cell Lung Cancer NSCLC 1Myelodysplastic Syndromes 1Melanoma 1Lung Neoplasms 1Leukemia 1High Grade Serous Carcinoma 1Fallopian Tube Neoplasms 1Extensive Stage Small Cell Lung Cancer 1Carcinosarcoma 1Carcinoma, Transitional Cell 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Carcinoma, Endometrioid 1Advanced Breast Cancer 1Adenocarcinoma 1

Interventions

Cyclophosphamide 361Trastuzumab 352Paclitaxel 304Docetaxel 272Capecitabine 222Letrozole 221Carboplatin 185Doxorubicin 181Tamoxifen 157Radiotherapy 154Epirubicin 145Fulvestrant 143Anastrozole 139Surveys and Questionnaires 133Exercise 128pertuzumab 113Vinorelbine 110Blood Specimen Collection 109exemestane 106palbociclib 104Bevacizumab 104pembrolizumab 98Magnetic Resonance Spectroscopy 97Albumin-Bound Paclitaxel 87Gemcitabine 84Drug Therapy 83Lapatinib 78130-nm albumin-bound paclitaxel 72Neoadjuvant Therapy 71Cisplatin 69

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Breast Neoplasms × ceralasertib × Clear all
NCT04090567 2026-03-05

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

M.D. Anderson Cancer Center

Phase 2 Recruiting
60 enrolled
Breast

Breast Neoplasms

NCT03740893 2025-08-11

PHOENIX

Institute of Cancer Research, United Kingdom

Phase 2 Recruiting
119 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡